8 / 18
Page 72
Notes:
conferenceseries
.com
Volume 2, Issue 3 (Suppl)
Breast Can Curr Res, an open access journal
ISSN: 2572-4118
Breast Cancer 2017
June 15-17, 2017
June 15-17, 2017 London, UK
5
th
World Congress on
Breast Cancer
Ik Shin Chin et al., Breast Can Curr Res 2017, 2:3(Suppl)
DOI: 10.4172/2572-4118-C1-006
An analysis of the use of neo-adjuvant chemotherapy with trastuzumab for patients with HER-2
positive breast cancer
Ik Shin Chin, Canada Cherry
and
Racha Kussaibati
Birmingham Heartlands Hospital, UK
U
se of anti-HER-2 therapy with chemotherapy in the neoadjuvant setting improves pathological complete response (PCR)
rate. Patients with HER2-overexpressing tumors who achieve PCR had better event-free survival and overall survival.
The proportion of patients achieving PCR with addition of neoadjuvant trastuzumab is 22.6-65.2%. Dual anti-HER-2 therapy
has been recommended in selected high risk cases. This study primary aim is to determine PCR rate in HER-2 positive breast
cancer patients who have received neoadjuvant chemotherapy and trastuzumab in the heart of England Foundation Trust,
and to identify their tumor characteristics. Secondary aims are to establish proportion of patients who had breast conserving
surgery and those who developed recurrence or metastases. Data was collected retrospectively to include cases from January
2011 to 2016 using the hospital electronic system. 18 patients were identified who had HER-2 positive invasive ductal carcinoma
and received neoadjuvant fluorouracil, epirubicin and cyclophosphamide followed by docetacel and trastuzumab 16(89%)
had a pathological response and 10(56%) had a complete pathological response. Among those who achieved PCR, 50% were
hormonal receptor negative and 70% had graded 3 tumors and positive lymph nodes. Overall, 44% of patients had breast
conserving surgery. One patient developed local recurrence and two patients had metastases. Our data showed that the rate of
PCR achieved in our unit is comparable with other studies. Patients with more aggressive tumors appeared to achieve a better
response however a larger sample size is needed to further strengthen this association.
Biography
Ik Shin Chin is a Specialty Registrar Trainee in medical oncology. She is currently working with the breast care team in the Heart of England NHS Foundation Trust
in Birmingham, West Midlands.
chinikshin@gmail.com